Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
about
Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examplesIron dysregulation in Huntington's diseaseIron chelation and multiple sclerosisPharmacology of iron transportIron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseasesMinding metals: tailoring multifunctional chelating agents for neurodegenerative disease.Redox control of prion and disease pathogenesis.1B/(-)IRE DMT1 expression during brain ischemia contributes to cell death mediated by NF-κB/RelA acetylation at Lys310Eryptosis as a marker of Parkinson's diseaseReactive oxygen species and inhibitors of inflammatory enzymes, NADPH oxidase, and iNOS in experimental models of Parkinson's disease.Haptoglobin phenotype modifies serum iron levels and the effect of smoking on Parkinson disease riskChelators in the treatment of iron accumulation in Parkinson's disease.Pharmacological inhibition of neuronal NADPH oxidase protects against 1-methyl-4-phenylpyridinium (MPP+)-induced oxidative stress and apoptosis in mesencephalic dopaminergic neuronal cellsIsatin: role in stress and anxiety.Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases.Multifunctional drugs with different CNS targets for neuropsychiatric disorders.Genetics of iron regulation and the possible role of iron in Parkinson's disease.A delicate balance: Iron metabolism and diseases of the brain.Glutathione metabolism and Parkinson's disease.Time- and cell-type specific changes in iron, ferritin, and transferrin in the gerbil hippocampal CA1 region after transient forebrain ischemiaNeuroprotection for Huntington's disease: ready, set, slowNutraceuticals against Neurodegeneration: A Mechanistic Insight.Targeting the progression of Parkinson's disease.Human interleukin-10 gene transfer is protective in a rat model of Parkinson's disease.Iron Chelators as Potential Therapeutic Agents for Parkinson's DiseaseNeurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a reviewMetal chelators coupled with nanoparticles as potential therapeutic agents for Alzheimer's diseaseInhibition of prolyl hydroxylase protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disease.Iron toxicity in neurodegeneration.Hypoxia-inducible factor prolyl hydroxylases as targets for neuroprotection by "antioxidant" metal chelators: From ferroptosis to stroke.Iron deposits in the chronically inflamed central nervous system and contributes to neurodegeneration.Advances in non-dopaminergic treatments for Parkinson's diseasePropargylamine as functional moiety in the design of multifunctional drugs for neurodegenerative disorders: MAO inhibition and beyond.Association of Lithium in Drinking Water With the Incidence of Dementia.The neurotoxicity of iron, copper and cobalt in Parkinson's disease through ROS-mediated mechanisms.Dysfunction of the neurovascular unit in ischemic stroke and neurodegenerative diseases: An aging effect.Systems Genetics Analysis of Iron and Its Regulation in Brain and Periphery.Smoking and haptoglobin phenotype modulate serum ferritin and haptoglobin levels in Parkinson disease.Rg1 protects iron-induced neurotoxicity through antioxidant and iron regulatory proteins in 6-OHDA-treated MES23.5 cells.
P2860
Q24289511-FE62101B-C312-4FC9-8CA1-4C5F6193632DQ26829932-1BF93352-CAC4-4807-B2ED-4C643604CF9FQ27001743-375E6BFE-32C7-4200-8A6B-66B6CD7C779EQ27009387-518650E2-F1E4-4CA4-B588-890B3C1D7483Q28388335-525BA97F-ABDD-453E-A3B3-C11656C03070Q33813567-F08F96A7-58F9-4770-82A4-D48F5864E2C2Q33830151-C70576E2-3038-4949-828D-E3645DA3B3A0Q34292783-9F1FD649-72D6-433A-82B5-EC003D9EA782Q34585744-A7A2BE35-8035-43AA-B035-5E2373DA9781Q35942562-C3C8313C-C031-4C0A-AFD8-1A06E16A17BDQ36011968-5E1025A6-5521-46C5-8ED9-58B9A09AE474Q36056203-735EBB05-82AB-43F6-84E9-3079877218F5Q36275187-63C04BEC-BF62-4888-B842-F98E595F2DB0Q36291275-273AD9FF-BDB2-401A-B8B5-40C5652130CDQ36499640-33CF8A19-2E1C-4F37-881E-DA5BEA0DA603Q36543057-47DDBE9A-4838-460B-9F9A-15696DE4D6BEQ36630021-4B515222-ABA6-46AE-AD12-63EC5CDE627AQ36815145-16084C2E-596F-44B7-B09A-5120C1E51985Q37023585-85D97486-B7BC-4ED2-8ADE-545857B7B9F3Q37078480-7B35251F-559D-4394-912D-13E488F058E4Q37129758-BA9E3194-39EC-474E-B714-4B284B8FF277Q37131243-B0CECB8F-3A53-4D06-8295-DB0F4CA41AC6Q37168739-80598047-973F-454F-94D9-CD11DAFF533AQ37299619-7834DFAE-1AFF-49AF-80A9-87875C3BF1A6Q37300999-E19FF684-BC19-4BA0-BCD1-925402267437Q37374312-0B87D0D6-E83A-4870-B410-B6D82D9C9F02Q37418238-F6388E93-37C6-40A4-9E88-EF65FA448FECQ37428097-671A0AF1-F183-495C-8DF1-3250AB560F1BQ37431242-9CE3F98F-B632-4268-A81F-1D9E197D1BE6Q37982648-BCF2A71A-0F74-455A-9CE6-7F98C86E1E0DQ38078689-2C33137F-68FC-4813-AAEE-4911CC479B90Q38161837-3B3F6413-6749-4528-B283-205C7C1A716DQ38218083-9C32E426-114B-4840-8B4E-A76039657C50Q38447289-C2C4B08B-C9B6-4E83-9F26-AEEB0EDE2FBBQ38612441-CF6A552C-3195-47E5-B862-AD4D39B4336BQ38878661-06AC0768-E644-4338-B8F2-783F6B8BFB18Q38971110-560AB443-7EE5-492A-B310-ECDB14444081Q39117039-98CC06A1-524C-448C-A3C8-3EF27BFA2C09Q39650753-FBA88379-6091-4400-8914-E0149961A036Q39651300-FC7C6596-5813-4C2F-9B69-56A883A138E3
P2860
Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Ironing iron out in Parkinson' ...... chelators, desferal and VK-28.
@en
Ironing iron out in Parkinson' ...... chelators, desferal and VK-28.
@nl
type
label
Ironing iron out in Parkinson' ...... chelators, desferal and VK-28.
@en
Ironing iron out in Parkinson' ...... chelators, desferal and VK-28.
@nl
prefLabel
Ironing iron out in Parkinson' ...... chelators, desferal and VK-28.
@en
Ironing iron out in Parkinson' ...... chelators, desferal and VK-28.
@nl
P2093
P356
P1476
Ironing iron out in Parkinson' ...... chelators, desferal and VK-28.
@en
P2093
Dorit Ben Shachar
Galia Stephenson
Moussa B H Youdim
P304
P356
10.1196/ANNALS.1306.025
P407
P577
2004-03-01T00:00:00Z